Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Integration of the DNA copy of the HIV-1 genome into a host chromosome is required for viral replication and is thus an important target for antiviral therapy. The HIV-encoded enzyme integrase (IN) catalyzes two essential steps: 3′ processing of the viral DNA ends, followed by the strand transfer reaction, which inserts the viral DNA into host DNA. Raltegravir binds to IN and blocks the integration of the viral DNA. Using the Rous sarcoma virus-derived vector RCAS, we previously showed that mutations that cause one viral DNA end to be defective for IN-mediated integration led to abnormal integrations in which the provirus had one normal and one aberrant end, accompanied by rearrangements in the host genome. On the basis of these results, we expected that suboptimal concentrations of IN inhibitors, which could block one of the ends of viral integration, would lead to similar aberrant integrations. In contrast to the proviruses from untreated cells, which were all normal, ∼10–15% of the proviruses isolated after treatment with a suboptimal dose of raltegravir were aberrant. The aberrant integrations were similar to those seen in the RCAS experiments. Most of the aberrant proviruses had one normal end and one aberrant end and were accompanied by significant rearrangements in the host genome, including duplications, inversions, deletions and, occasionally, acquisition of sequences from other chromosomes. The rearrangements of the host DNA raise concerns that these aberrant integrations might have unintended consequences in HIV-1–infected patients who are not consistent in following a raltegravir-containing treatment regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 1×
“RAL has a much smaller effect on the 3′ processing of the viral DNA ends than on the insertion of viral DNA (17).”
BackgroundRetroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678
Brown, P. O., Bowerman, B., Varmus, H. E., & Bishop, J. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.8.2525 · Cited by 399
Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance
Hare, S., Vos, A. M., Clayton, R. F., Thuring, J. W., Cummings, M. D., & Cherepanov, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010246107 · Cited by 305 · cited 1×
“4 (IC14) 5 34 159 (13) 20 (18) 13 (53) 384”
Cited by
A New Class of Multimerization Selective Inhibitors of HIV-1 Integrase
Sharma, A., Slaughter, A., Jena, N., Feng, L., Kessl, J. J., Fadel, H. J., Malani, N., Male, F., Wu, L., Poeschla, E., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004171 · Cited by 124
“A recent report [61] has shown that the treatment of infected cells with suboptimal concentrations of RAL leads to aberrant HIV-1 integration, which results in significant rearrangements in the host genome.”
BackgroundEfficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
Smith, S. J., Zhao, X. Z., Burke, T. R., & Hughes, S. H. (2018) · Retrovirology · doi:10.1186/s12977-018-0420-7 · Cited by 114
Self-citationDemeulemeester, J., Vets, S., Schrijvers, R., Madlala, P., De Maeyer, M., De Rijck, J., Ndung’u, T., Debyser, Z., & Gijsbers, R. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.09.016 · Cited by 43
Janssens, J., De Wit, F., Parveen, N., & Debyser, Z. (2022) · mBio · doi:10.1128/mbio.00007-22 · Cited by 28
Metadata
- Authors
- Varadarajan, J., McWilliams, M. J., & Hughes, S. H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-08-19
- Volume
- 110
- Issue
- 36
- Pages
- 14747-14752
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2053165243
- Cited by
- 29
- References
- 4
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations. https://app.cochat.ai/papers/10.1073/pnas.1305066110
- The paper
- Varadarajan, J., McWilliams, M. J., & Hughes, S. H. (2013). Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1305066110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.